BOHA approves use of Vyvanse for binge eating disorder
The Healing Arts Act at KSA 65-2837 limits the prescribing of amphetamines or sympathomimetic amine controlled substances to treatments for specific diagnoses but allows non-specified disorders to be treated as well, as long as such treatment is safe, effective, supported by scientific research and with the general support of the scientific community.
These statutes were approved in 1984, before the American Psychiatric Association formally recognized Binge Eating Disorder (B.E.D.) in 2013 as a distinct psychiatric disorder. An estimated 2.8 million US adults suffer from B.E.D., making it more prevalent in the U.S. than anorexia nervosa and bulimia nervosa combined.
The FDA has since approved Vyvanse, a sympathomimetic amine, as a treatment for moderate to severe B.E.D. in adults. There are no other pharmacologic treatments approved for this condition at this time. In light of these facts, at the August 14 meeting, the Board of Healing Arts considered and approved a petition allowing for use of Vyvanse in treating B.E.D.
If you have questions about this issue or other legislative matters, please contact Director of Government Affairs, Rachelle Colombo.
ICD-10 resources now available
Fewer than five weeks remain until the nation switches from ICD-9 to ICD-10 coding for medical diagnoses and inpatient hospital procedures. (Click here for more information)